|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Blood, 15 February 2005, Vol. 105, No. 4, pp. 1374.
Tissue factor and tumor cells: as bad as it gets?THE SCRIPPS RESEARCH INSTITUTE
Yu and colleagues have characterized sequential transforming events that drive the up-regulation of tissue factor on colorectal tumor cells. Furthermore, tissue factor expression defines the aggressive character of these cells in vivo.
Tissue factor has also been found up-regulated on primary tumor cells, and many tumors show a dramatically increased procoagulant activity. Surprisingly, very little is known about the molecular mechanism underlying tissue factor overexpression in cancer cells and the impact of tissue factor overexpression on primary tumor growth. In this issue, Yu and colleagues unravel the nature of the transformation events that lead to deregulated tissue factor production in colorectal cancer cells. They show that K-ras and p53 mutation lead to a cumulative overexpression of both cell surface–exposed tissue factor and circulating tissue factor in the plasma of tumor-bearing mice. Expression of tissue factor was found to be required for the full manifestation of both tumor angiogenesis and aggressive tumor cell behavior in vivo, possibly via regulation of the antiangiogenic factors thrombospondin-1 and 2. Interestingly, tissue factor expression is not a transforming event per se; tissue factor–associated aggressiveness was found to be strictly dependent on the host environment, since tissue factor dramatically influenced tumor growth properties in vivo but did not alter growth properties in vitro. Therefore, although highly speculative, this finding may point toward a role for tissue factor ligands, such as factor VII/VIIa or plasminogen, in oncogenic events. Since both hemostatic factors have been shown to induce tissue factor–dependent intracellular signaling cascades, they may be the direct trigger of tissue factor–associated tumor cell aggressiveness.2,5 Alternatively, activation of downstream coagulation factors such as FX or prothrombin may facilitate this process.
Understanding the role of tissue factor in primary tumor growth may be of vital importance for the development of new anticancer therapies. Directly targeting the transforming oncogenes is often not feasible, whereas blockade of downstream events, such as tissue factor function, may be more effective. Thus, the work described by Yu et al provides valuable information that may facilitate the use of tissue factor–blocking strategies in cancer. References
  CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||||
 |
 |
 |
 |
 |
 |
 |
 |
||||
| |||||||||||
| Copyright © 2005 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||||
